European Companies Search Engine
EU funding (€4,674,996): OPTIMISING COLORECTAL CANCER PREVENTION TROUGH PERSONALISED TREATMENT WITH ARTIFICIAL INTELLIGENCE Hor2 Aug 2022 EU Research and Innovation programme "Horizon"
Text
OPTIMISING COLORECTAL CANCER PREVENTION TROUGH PERSONALISED TREATMENT WITH ARTIFICIAL INTELLIGENCE
Integration of artificial intelligence (AI) technologies into clinical medicine has been hampered by challenges related to uncertain long-term clinical benefits, cost-effectiveness, and ethics/legal concerns. Application of AI in colonoscopy, a forefront research topic, has been also bothered by these issues. AI is, however, expected to reduce colorectal cancer incidence and mortality through personalised treatment. Our proposed project would change this discouraging situation and thus drastically improves colorectal cancer care. We achieve the following goals: 1. Establish the value of AI-assisted colonoscopy in colorectal cancer prevention by conducting a pan-European, population-based, randomised trial with 222,000 participants. 2. Develop a colonoscopy AI risk-prediction tool for personalized treatment of colorectal polyps and cancer. 3. Develop cost-effectiveness models of AI-assisted colonoscopy in colorectal cancer screening. 4. Investigate ethical and legal barriers in AI development and implementation. 5. Generate the first trustworthy and rapidly updating (?living?) clinical guidelines for AI in screening colonoscopy. 6. Develop a patient-oriented AI tool by including end-users in the process of AI development and communication. Our research consortium maximises the feasibility of the project, with world-class experts in gastroenterology, machine learning, cancer screening, biostatistics, disease modelling, regulatory science, and ethics and law in medicine from nine European countries, the US and Japan. We also partner with a European medium-size AI enterprise for implementing the output of the project. The project has large potential impact on patients, society, and economy in Europe, and the World. Up to 6,000 fewer deaths due to colorectal cancer and saving of 720 million euro can be expected per year once the technology is widely accepted in Europe.
Funded Companies:
| Company name | Funding amount |
| King's College Hospital NHS Foundation Trust | ? |
| Aarhus Universitet | €250,000 |
| BETH ISRAEL DEACONESS MEDICAL CENTER, INC NON PROFIT CORPORATION | €50,000 |
| Ethniko Kai Kapodistriako Panepistimio Athinon | €50,000 |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | €250,000 |
| Hospital Clinic de Barcelona | €0.00 |
| Humanitas Mirasole S.p.A. | €250,000 |
| Karolinska Institutet | €250,000 |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie -Panstwowy Instytut Badawczy | €250,000 |
| Oslo Universitetssykehus HF | €1,000,001 |
| Stiftelsen Magic Evidence Ecosystem | €300,000 |
| THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | €61,952 |
| THE PENNSYLVANIA STATE UNIVERSITY | €38,048 |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | €75,000 |
| Universitetet I Oslo | €1,849,995 |
Source: https://cordis.europa.eu/project/id/101057099
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: King's College Hospital NHS Foundation Trust, London.
